Médunik, Biocodex sign exclusive agreement for Diacomit in Canada

Médunik Canada has entered into an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome. The arrangement aims to use Médunik Canada’s expertise in rare diseases to boost relationships with Canadian epilepsy specialists and centres. Dravet syndrome is described as a rare lifelong neurological disorder marked by frequent, often treatment-resistant seizures from infancy. Credit: one photo / Shutterstock.com. Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome.…

Source: Pharmaceutical Technology